Definium Therapeutics, Inc.
Support and Resistance Levels
Past performance
News About DFTX
All events for DFTX
All deals for DFTX
Financial Ratios
Financial Statements
DFTX vs Sector & Peers
About Definium Therapeutics, Inc.
Definium Therapeutics, Inc. operates as a clinical-stage biopharmaceutical firm dedicated to developing innovative therapeutic solutions for various brain health and neurological disorders. Its pipeline features key experimental drug candidates like MM120, which is currently undergoing Phase 3 clinical trials for generalized anxiety disorder (GAD) and attention deficit hyperactivity disorder (ADHD). Another significant compound, MM402 – an R-enantiomer of 3,4-methylenedioxymethamphetamine – is in Phase 1 trials, targeting the fundamental symptoms of autism spectrum disorder. The company maintains its headquarters in New York, New York. Website definiumtx.com
Headquarters New York, NY, US